This report describes and explains the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market reached a value of nearly $2.89 billion in 2025, having grown at a compound annual growth rate (CAGR) of 8% since 2020. The market is expected to grow from $2.89 billion in 2025 to $4.12 billion in 2030 at a rate of 7.4%. The market is then expected to grow at a CAGR of 6.7% from 2030 and reach $5.69 billion in 2035.
Growth in the historic period resulted from shift towards expansion of clinical trials and robust therapeutic pipeline, shift toward personalized and precision medicine, rising research and development (R&D) spending in life sciences and stringent regulatory and GMP compliance requirements. Factors that negatively affected growth in the historic period were high manufacturing and operational costs, limited availability of skilled workforce.
Going forward, rising prevalence of chronic and metabolic diseases, growing adoption of peptide therapeutics, expanding biopharmaceutical industry and greater use of peptides in specialty care will drive the growth. Factors that could hinder the growth of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market in the future include capacity and scalability limitations, dependence on specialized raw materials and impact of trade war and tariff.
Market trends for the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market include emphasis on cloud-based platforms and big data analytics; adopting greener chemistry principles, solvent recycling systems, and energy-efficient purification technologies, advanced automation, continuous processing, and digitally integrated production systems; leveraging AI-driven models to predict peptide synthesis outcomes and advances in biotechnology, genomics, and precision medicine.
The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market is segmented by scale of operation into preclinical or clinical and commercial. The commercial market was the largest segment of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by scale of operation, accounting for 80% or $2.31 billion of the total in 2025. Going forward, the preclinical or clinical segment is expected to be the fastest growing segment in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by scale of operation, at a CAGR of 7.8% during 2025-2030.
The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market is segmented by synthesis method into non-chemical synthesis and chemical synthesis. The chemical synthesis was the largest segment of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by synthesis method, accounting for 83.3% or $2.4 billion of the total in 2025. Going forward, the non chemical synthesis segment is expected to be the fastest growing segment in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by synthesis method, at a CAGR of 8.7% during 2025-2030.
The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market is segmented by enterprise type into large enterprise and small and medium enterprises. The large enterprise market was the largest segment of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by enterprise type, accounting for 66.7% or $1.92 billion of the total in 2025. Going forward, the small and medium enterprises segment is expected to be the fastest growing segment in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by enterprise type, at a CAGR of 8.6% during 2025-2030.
North America was the largest region in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market, accounting for 8.1% or $1.05 billion of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market will be Asia Pacific and Africa where growth will be at CAGRs of 8.7% and 8.3% respectively. These will be followed by Eastern Europe and Middle East where the markets are expected to grow at CAGRs of 8.2% and 7.9% respectively.
The global peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market is concentrated, with a large players dominating across major regions. The top 10 competitors in the market made up 47.8% of the total market in 2024. Bachem Group was the largest competitor with a 12.4% share of the market, followed by PolyPeptide Group with 10.9%, CordenPharma International GmbH with 8.6%, Ambiopharm Inc. with 6%, Asymchem Laboratories (Tianjin) Co Ltd. with 3%, Aspen Holdings (Aspen API) with 2.4%, WuXi AppTec Co. Ltd. with 1.5%, Piramal Pharma Solutions (PPS) with 1.3%, GenScript Biotech Corporation with 0.9% and ScinoPharm Taiwan Ltd. with 0.7%.
The top opportunities in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by scale of operation will arise in the commercial segment, which will gain $3.28 billion of global annual sales by 2030. The top opportunities in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by synthesis method will arise in the chemical synthesis segment, which will gain $3.39 billion of global annual sales by 2030. The top opportunities in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by enterprise type will arise in the large enterprise segment, which will gain $2.67 billion of global annual sales by 2030. The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market size will gain the most in the USA at $351.6 million.
Player-adopted strategies in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market include focus on enhancing operational capabilities through expanding their manufacturing capacities, focus on enhancing operational capabilities through expanding strategic partnerships and focus on expanding business expertise through new innovations.
Market-trend-based strategies for the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market include focus on expanding flexible manufacturing capabilities, focus on scaling commercial-grade manufacturing infrastructure, focus on adopting integrated end-to-end manufacturing platforms, focusing on advancing high-purity solid-phase peptide synthesis (SPPS) capabilities by commissioning new large-scale SPPS production assets, focus on launching and adopting hybrid peptide synthesis approaches and fous on strengthening Good Manufacturing Practice (GMP)-compliant production.
To take advantage of the opportunities, the analyst recommends the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing companies to focus on expanding flexible early-stage manufacturing capabilities, focus on scaling commercial-grade peptide API manufacturing capacity, focus on adopting integrated end-to-end peptide API manufacturing platforms, focus on advancing high-purity solid-phase peptide synthesis (SPPS) capabilities, focus on adopting hybrid peptide synthesis approaches, focus on strengthening GMP-compliant peptide API production, focus on expanding commercial-scale peptide API manufacturing, focus on expanding non-chemical peptide API manufacturing, expand in emerging markets, continue to focus on developed markets, focus on value-based and tiered pricing strategies, focus on targeted scientific marketing and thought leadership, focus on strategic client engagement and relationship marketing and focus on supporting small and medium enterprise clients.
This product will be delivered within 3-5 business days.
The global peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market reached a value of nearly $2.89 billion in 2025, having grown at a compound annual growth rate (CAGR) of 8% since 2020. The market is expected to grow from $2.89 billion in 2025 to $4.12 billion in 2030 at a rate of 7.4%. The market is then expected to grow at a CAGR of 6.7% from 2030 and reach $5.69 billion in 2035.
Growth in the historic period resulted from shift towards expansion of clinical trials and robust therapeutic pipeline, shift toward personalized and precision medicine, rising research and development (R&D) spending in life sciences and stringent regulatory and GMP compliance requirements. Factors that negatively affected growth in the historic period were high manufacturing and operational costs, limited availability of skilled workforce.
Going forward, rising prevalence of chronic and metabolic diseases, growing adoption of peptide therapeutics, expanding biopharmaceutical industry and greater use of peptides in specialty care will drive the growth. Factors that could hinder the growth of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market in the future include capacity and scalability limitations, dependence on specialized raw materials and impact of trade war and tariff.
Market trends for the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market include emphasis on cloud-based platforms and big data analytics; adopting greener chemistry principles, solvent recycling systems, and energy-efficient purification technologies, advanced automation, continuous processing, and digitally integrated production systems; leveraging AI-driven models to predict peptide synthesis outcomes and advances in biotechnology, genomics, and precision medicine.
The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market is segmented by scale of operation into preclinical or clinical and commercial. The commercial market was the largest segment of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by scale of operation, accounting for 80% or $2.31 billion of the total in 2025. Going forward, the preclinical or clinical segment is expected to be the fastest growing segment in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by scale of operation, at a CAGR of 7.8% during 2025-2030.
The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market is segmented by synthesis method into non-chemical synthesis and chemical synthesis. The chemical synthesis was the largest segment of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by synthesis method, accounting for 83.3% or $2.4 billion of the total in 2025. Going forward, the non chemical synthesis segment is expected to be the fastest growing segment in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by synthesis method, at a CAGR of 8.7% during 2025-2030.
The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market is segmented by enterprise type into large enterprise and small and medium enterprises. The large enterprise market was the largest segment of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by enterprise type, accounting for 66.7% or $1.92 billion of the total in 2025. Going forward, the small and medium enterprises segment is expected to be the fastest growing segment in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by enterprise type, at a CAGR of 8.6% during 2025-2030.
North America was the largest region in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market, accounting for 8.1% or $1.05 billion of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market will be Asia Pacific and Africa where growth will be at CAGRs of 8.7% and 8.3% respectively. These will be followed by Eastern Europe and Middle East where the markets are expected to grow at CAGRs of 8.2% and 7.9% respectively.
The global peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market is concentrated, with a large players dominating across major regions. The top 10 competitors in the market made up 47.8% of the total market in 2024. Bachem Group was the largest competitor with a 12.4% share of the market, followed by PolyPeptide Group with 10.9%, CordenPharma International GmbH with 8.6%, Ambiopharm Inc. with 6%, Asymchem Laboratories (Tianjin) Co Ltd. with 3%, Aspen Holdings (Aspen API) with 2.4%, WuXi AppTec Co. Ltd. with 1.5%, Piramal Pharma Solutions (PPS) with 1.3%, GenScript Biotech Corporation with 0.9% and ScinoPharm Taiwan Ltd. with 0.7%.
The top opportunities in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by scale of operation will arise in the commercial segment, which will gain $3.28 billion of global annual sales by 2030. The top opportunities in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by synthesis method will arise in the chemical synthesis segment, which will gain $3.39 billion of global annual sales by 2030. The top opportunities in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market segmented by enterprise type will arise in the large enterprise segment, which will gain $2.67 billion of global annual sales by 2030. The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market size will gain the most in the USA at $351.6 million.
Player-adopted strategies in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market include focus on enhancing operational capabilities through expanding their manufacturing capacities, focus on enhancing operational capabilities through expanding strategic partnerships and focus on expanding business expertise through new innovations.
Market-trend-based strategies for the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market include focus on expanding flexible manufacturing capabilities, focus on scaling commercial-grade manufacturing infrastructure, focus on adopting integrated end-to-end manufacturing platforms, focusing on advancing high-purity solid-phase peptide synthesis (SPPS) capabilities by commissioning new large-scale SPPS production assets, focus on launching and adopting hybrid peptide synthesis approaches and fous on strengthening Good Manufacturing Practice (GMP)-compliant production.
To take advantage of the opportunities, the analyst recommends the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing companies to focus on expanding flexible early-stage manufacturing capabilities, focus on scaling commercial-grade peptide API manufacturing capacity, focus on adopting integrated end-to-end peptide API manufacturing platforms, focus on advancing high-purity solid-phase peptide synthesis (SPPS) capabilities, focus on adopting hybrid peptide synthesis approaches, focus on strengthening GMP-compliant peptide API production, focus on expanding commercial-scale peptide API manufacturing, focus on expanding non-chemical peptide API manufacturing, expand in emerging markets, continue to focus on developed markets, focus on value-based and tiered pricing strategies, focus on targeted scientific marketing and thought leadership, focus on strategic client engagement and relationship marketing and focus on supporting small and medium enterprise clients.
This product will be delivered within 3-5 business days.
Table of Contents
1 Executive Summary
6 Market Characteristics
8 Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Attractiveness Scoring and Analysis
9 Major Market Trends
10 Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market - Macro Economic Scenario
13 Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Growth Analysis and Strategic Analysis Framework
14 Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Size and Growth Analysis
15 Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Total Addressable Market (TAM) Analysis
16 Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Segmentation
17 Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Regional and Country Analysis
18 Asia-Pacific Market
19 South East Asia Market
20 North America Market
21 Western Europe Market
22 South America Market
23 Eastern Europe Market
24 Middle East Market
25 Africa Market
26 Competitive Landscape and Company Profiles
27 Other Major and Innovative Companies
30 USA Competitive Landscape and Company Profiles
31 Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market - Company Scoring Matrix
33 Key Mergers and Acquisitions
34 Recent Developments in Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing
35 Opportunities and Strategies
36 Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Conclusions and Recommendations
37 Appendix
Executive Summary
Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Global Market Opportunities and Strategies to 2035 provides the strategists; marketers and senior management with the critical information they need to assess the global peptide therapeutics contract API manufacturing market as it emerges from the COVID-19 shut down.Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for peptide therapeutics contract API manufacturing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peptide therapeutics contract API manufacturing market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider peptide therapeutics contract API manufacturing market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics Brief introduction to the segmentations covered in the market, definitions and explanations about the segments, key products, supply chain and market attractiveness scoring and analysis.
- Key Trends Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Growth Analysis and Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Regional and Country Analysis Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
- Market Segmentation Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by scale of operation, by synthesis method and by enterprise type in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
- Regional Market Size and Growth Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major and Innovative Companies Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking Briefs on the financials comparison between major players in the market.
- Competitive Dashboard Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
- Recent Developments Information on recent developments in the market covered in the report.
- Market Opportunities and Strategies-Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions and Recommendations-This section includes recommendations for peptide therapeutics contract API manufacturing providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Markets Covered:
1) By Scale Of Operation: Preclinical Or Clinical; Commercial
2) By Synthesis Method: Non Chemical Synthesis; Chemical Synthesis
3) By Enterprise Type: Large Enterprise; Small and Medium Enterprises
Countries: China; Australia; India; Indonesia; Japan; South Korea; Taiwan; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa; South East Asia
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; peptide therapeutics contract API manufacturing indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- Bachem Group
- PolyPeptide Group
- CordenPharma International GmbH
- Ambiopharm Inc
- Asymchem Laboratories (Tianjin) Co Ltd.
- Aspen Holdings (Aspen API)
- WuXi AppTec Co. Ltd.
- Piramal Pharma Solutions (PPS)
- GenScript Biotech Corporation
- ScinoPharm Taiwan Ltd
- Thermo Fisher Scientific
- Shanghai ChemPartner Co., Ltd.
- Syngene International Limited
- Auspep
- Chinese Peptide Company Ltd.
- CPC Scientific
- ScinoPharm Taiwan, Ltd.
- Lonza Australia
- IDT Australia
- SK pharmteco
- Eli Lilly and Company
- Anthem Biosciences Ltd
- Neuland Laboratories Ltd
- Sinopep-Allsino Biopharmaceutical Co., Ltd.
- Zhejiang Jiuzhou Pharmaceutical Co Ltd
- PeptiStar Inc.
- Fujimoto Chemicals Co., Ltd.
- The Merck Group
- Leadgene Biomedical
- Lonza Group
- APD Pharmaceutical
- NeoBioLab Co., Ltd.
- Apical Scientific Sdn Bhd
- Hybio Pharmaceutical Co. Ltd
- Senn Chemicals
- Apex Biotechnology Corporation
- Big Bear Pharmaceutical Co., Ltd.
- Huarong Pharm
- Bristo Pharmaceutical Company Canada
- CEM Corporation
- AnaSpec Inc.
- CSBio
- Patheon
- Dalton Pharma Services
- Canada Peptide
- Therapure BioPharma Inc.
- BCN Peptides
- Axplora
- Olon S.p.A.
- Azenta Life Sciences
- Aspen Pharmacare
- Eva Pharma
- Emzor Pharmaceuticals
- Fidson Healthcare Plc
